Calliditas Therapeutics announced the initiation of a Phase 2 clinical study to evaluate setanaxib in Alport syndrome. Calliditas is a company focused on developing and commercializing novel treatments in rare diseases with significant unmet medical needs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CALT:
- Calliditas announces Everest Medicines receives approval for Nefecon
- Omeros’ failure alleviates competition for Calliditas, says H.C. Wainwright
- Calliditas Therapeutics announces COMP opinion on setanaxib
- Calliditas Therapeutics presents Phase 3 NefIgArd study data
- Calliditas Therapeutics partner submits request to MHRA to convert Kinpeygo CMA
